B8063
BML-210
≥98% (HPLC), powder
别名:
N1-(2-aminophenyl)-N8-phenyl-octanediamide
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C20H25N3O2
化学文摘社编号:
分子量:
339.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to very faintly yellow
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
SMILES string
Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2
InChI
1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)
InChI key
RFLHBLWLFUFFDZ-UHFFFAOYSA-N
Biochem/physiol Actions
BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.
BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM.
BML-210 is an HDAC inhibitor.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable